

# Atara Biotherapeutics to Host CAR T Breakfast Teach-In on November 29, 2018

SOUTH SAN FRANCISCO, Calif., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that the Company will host a live conference call and webcast in conjunction with its CAR T Breakfast Teach-In on Thursday, November 29, 2018 at 7:30 a.m. EST in New York, NY.

The event features next generation CAR T experts:

- Michel Sadelain, M.D., Ph.D., Director, Center for Cell Engineering, Memorial Sloan Kettering Cancer Center (MSK)
- Marco Davila, M.D., Ph.D., Associate Attending Physician, Department of Blood & Marrow Transplantation and Cellular Immunotherapy Medical Director, Cell Therapy Facility, Moffitt Cancer Center

#### **About Atara Biotherapeutics, Inc.**

Atara Biotherapeutics, Inc. (@Atarabio) is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara's most advanced T-cell immunotherapy, tab-cel<sup>®</sup> (tabelecleucel), is in Phase 3 development for patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder (EBV+ PTLD), as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma (NPC). Atara is also developing T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis (MS). Atara's pipeline also includes next generation chimeric antigen receptor T-cell (CAR T) immunotherapies for patients with hematologic and solid tumors, autoimmune and infectious diseases. The company was founded in 2012 and is headquartered in South San Francisco, California.

### **INVESTOR & MEDIA CONTACTS:**

#### Investors:


John Craighead, Atara Biotherapeutics 650-410-3012 <a href="mailto:jcraighead@atarabio.com">jcraighead@atarabio.com</a>

John Grimaldi, Burns McClellan

212-213-0006 x362 jgrimaldi@burnsmc.com

## Media:

Nancie Steinberg, Burns McClellan 212-213-0006 x318 nsteinberg@burnsmc.com



Source: Atara Biotherapeutics, Inc.